These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 29190165)
61. The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size. Vilaltella M; Huerva V Arq Bras Oftalmol; 2021; 85(2):109-114. PubMed ID: 34431893 [TBL] [Abstract][Full Text] [Related]
62. Long-Term Efficacy and Safety of Subconjunctival/Perilesional 5-Fluorouracil Injections for Ocular Surface Squamous Neoplasia. Sun Y; Hua R Drug Des Devel Ther; 2020; 14():5659-5665. PubMed ID: 33376309 [TBL] [Abstract][Full Text] [Related]
63. Predictors of Ocular Surface Squamous Neoplasia and Conjunctival Squamous Cell Carcinoma among Ugandan Patients: A Hospital-based Study. Lloyd HCM; Arunga S; Twinamasiko A; Frederick MA; Onyango J Middle East Afr J Ophthalmol; 2018; 25(3-4):150-155. PubMed ID: 30765953 [TBL] [Abstract][Full Text] [Related]
64. Recombinant Interferon Alpha-2b as Primary Treatment for Ocular Surface Squamous Neoplasia. Ghaffari R; Barijani S; Alivand A; Latifi G; Ghassemi H; Zarei-Ghanavati M; Djalilian AR J Curr Ophthalmol; 2021; 33(3):260-265. PubMed ID: 34765812 [TBL] [Abstract][Full Text] [Related]
65. Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review. Viani GA; Fendi LI Arq Bras Oftalmol; 2017; 80(2):131-136. PubMed ID: 28591290 [TBL] [Abstract][Full Text] [Related]
75. Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia. Bahrami B; Greenwell T; Muecke JS Clin Exp Ophthalmol; 2014; 42(4):317-22. PubMed ID: 23927413 [TBL] [Abstract][Full Text] [Related]
76. Recurrence of Ocular Surface Squamous Neoplasia Treated With Excisional Biopsy and Cryotherapy. Li AS; Shih CY; Rosen L; Steiner A; Milman T; Udell IJ Am J Ophthalmol; 2015 Aug; 160(2):213-219.e1. PubMed ID: 25914042 [TBL] [Abstract][Full Text] [Related]
77. Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists. Meel R; Dhiman R; Vanathi M; Sen S; Gupta N; Tandon R Oman J Ophthalmol; 2021; 14(1):27-32. PubMed ID: 34084031 [TBL] [Abstract][Full Text] [Related]
78. Prevalence and Severity of Ocular Surface Neoplasia in African Nations and Need for Early Interventions. Reynolds JW; Pfeiffer ML; Ozgur O; Esmaeli B J Ophthalmic Vis Res; 2016; 11(4):415-421. PubMed ID: 27994810 [TBL] [Abstract][Full Text] [Related]
79. Ocular surface squamous neoplasia: management and outcomes. Hӧllhumer R; Williams S; Michelow P Eye (Lond); 2021 Jun; 35(6):1562-1573. PubMed ID: 33564137 [TBL] [Abstract][Full Text] [Related]
80. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. Vann RR; Karp CL Ophthalmology; 1999 Jan; 106(1):91-7. PubMed ID: 9917787 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]